Amedisys Inc (NASDAQ:AMED) insider David L. Kemmerly sold 6,500 shares of Amedisys stock in a transaction that occurred on Friday, November 9th. The stock was sold at an average price of $118.87, for a total value of $772,655.00. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.
David L. Kemmerly also recently made the following trade(s):
- On Wednesday, November 7th, David L. Kemmerly sold 3,375 shares of Amedisys stock. The stock was sold at an average price of $117.44, for a total value of $396,360.00.
NASDAQ:AMED traded up $1.46 on Friday, reaching $120.50. The company’s stock had a trading volume of 476,700 shares, compared to its average volume of 343,222. Amedisys Inc has a 12-month low of $49.80 and a 12-month high of $127.38. The company has a quick ratio of 1.06, a current ratio of 1.06 and a debt-to-equity ratio of 0.12. The company has a market capitalization of $3.57 billion, a P/E ratio of 54.53, a P/E/G ratio of 1.67 and a beta of 1.22.
Several hedge funds and other institutional investors have recently modified their holdings of AMED. Itau Unibanco Holding S.A. acquired a new stake in shares of Amedisys in the second quarter valued at $149,000. Moneta Group Investment Advisors LLC acquired a new stake in shares of Amedisys in the second quarter valued at $181,000. Cubist Systematic Strategies LLC grew its stake in shares of Amedisys by 1,086.0% in the second quarter. Cubist Systematic Strategies LLC now owns 2,372 shares of the health services provider’s stock valued at $203,000 after buying an additional 2,172 shares in the last quarter. Dorsey & Whitney Trust CO LLC acquired a new stake in shares of Amedisys in the third quarter valued at $203,000. Finally, Quantitative Systematic Strategies LLC acquired a new stake in shares of Amedisys in the second quarter valued at $217,000. 93.58% of the stock is owned by institutional investors and hedge funds.
A number of equities analysts recently commented on AMED shares. Royal Bank of Canada lifted their price objective on Amedisys to $115.00 and gave the stock an “outperform” rating in a research report on Friday, August 3rd. Robert W. Baird lifted their price objective on Amedisys from $105.00 to $120.00 and gave the stock a “neutral” rating in a research report on Thursday, October 11th. Bank of America set a $139.00 price objective on Amedisys and gave the stock a “buy” rating in a research report on Tuesday, September 18th. BidaskClub downgraded Amedisys from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, October 16th. Finally, Cantor Fitzgerald started coverage on Amedisys in a research report on Thursday, September 13th. They set a “neutral” rating and a $117.00 price objective on the stock. Five equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $105.50.
WARNING: This piece was originally posted by WKRB News and is owned by of WKRB News. If you are accessing this piece on another site, it was stolen and republished in violation of international copyright & trademark laws. The legal version of this piece can be viewed at https://www.wkrb13.com/2018/11/10/amedisys-inc-amed-insider-david-l-kemmerly-sells-6500-shares.html.
Amedisys Company Profile
Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, and aides for its patients to complete their important personal tasks.
Featured Story: What does EPS mean?
Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.